Home › Multiple Myeloma › Texas
Multiple Myeloma clinical trials in Texas
53 studies for Multiple Myeloma are looking for participants at sites in Texas.
Cities in Texas
- Houston38 studies
- Dallas17 studies
- Austin8 studies
- San Antonio6 studies
- The Woodlands4 studies
- Tyler4 studies
- Lubbock3 studies
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Austin
- Research Site, Dallas
- Research Site, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05652335A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- MD Anderson, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07336472A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- MD Anderson Cancer Center, Houston
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05201781A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- St. David's South Austin Medical Center, Austin
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07258511A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Texas Southwestern Medical Center, Dallas
- Houston Methodist Hospital, Houston
- Joe Arrington Cancer Research Treatment Center, Lubbock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05552222A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
- Research Site, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07073547A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Baylor University Medical Center, Dallas
- Joe Arrington Cancer Research Treatment Center, Lubbock
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07518186A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05623020A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07477587TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Texas Oncology - The Woodlands /ID# 278726, The Woodlands
- Texas Oncology - Northeast Texas /ID# 278725, Tyler
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07095452Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
All ages · All sexes · Updated Sep 18, 2026 · NCT07382739Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04879043A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06615479A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06953960Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- UT Southwestern Medical Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06297226A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06988488A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
- Research Site, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07681596MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
- Houston Methodist Cancer Center Infusion, Houston
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06152575A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Fort Worth
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05714839A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06292780A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Austin
- Research Site, Dallas
- Research Site, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05850234Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
- MD Anderson Cancer Center, Houston
RecruitingPhase 2Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT05091372Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Dallas
- Research Site, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Baylor University Medical Center, Dallas
- Houston Methodist Hospital, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT07280013Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06105554Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 10, 2026 · NCT06207799Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 12 to 80 · All sexes · Updated Aug 7, 2026 · NCT05092451A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- START San Antonio, San Antonio
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07284758A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT06892522A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06121843A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Texas Oncology - Central/South Texas /ID# 268563, Austin
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
- Oncology Consultants /ID# 268323, Houston
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of Texas Southwestern, Dallas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 8, 2026 · NCT05137054Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- St. David's South Austin Medical Center, Austin
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06057402Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- MD Anderson in The Woodlands, Conroe
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- and 6 more
RecruitingPhase 3
All ages · All sexes · Updated Jun 10, 2026 · NCT05561387Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Jun 8, 2026 · NCT05776979Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Texas Southwestern, Dallas
RecruitingPhase 2
Ages 19 and older · All sexes · Updated Jun 4, 2026 · NCT06974786From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.